RecruitingPhase 2NCT06620835
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Principal Investigator
- Jean-Bernard AULIACCentre Hospitalier Intercommunal de Créteil Service Pneumologie
- Intervention
- Blood samples for Hematology(biological)
- Enrollment
- 45 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (27)
- CHU de Brest, Brest, France
- Centre François Baclesse, Caen, France
- CH Métropole-Savoie, Chambéry, France
- Hôpital Louis Pasteur, Colmar, France
- Pneumologie Centre Hospitalier Intercommunal de Créteil, Créteil, France
- Centre Georges-François Leclerc, Dijon, France
- CH Annecy, Épagny, France
- Polyclinique de Blois, La Chaussée-Saint-Victor, France
- CHD les Oudaries, La Roche-sur-Yon, France
- CHU Dupuytren, Limoges, France
- Centre Leon Bérard, Lyon, France
- Hôpital Nord, Marseille, France
- CHRU de Nancy, Nancy, France
- CLCC Antoine Lacassagne, Nice, France
- CHU de Nîmes, Nîmes, France
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06620835 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
- RECRUITINGPHASE3NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Revolution Medicines, Inc.
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →